← Back to Search

Procedure

DMR for Type 2 Diabetes (REVITALIZE 1 Trial)

N/A
Recruiting
Research Sponsored by Fractyl Laboratories, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male, and non-pregnant, non-lactating females
Age between 21 and 70 years (both inclusive)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 24
Awards & highlights

REVITALIZE 1 Trial Summary

This trial is investigating whether a new diabetes treatment is better than a sham treatment at improving glycemic, hepatic, and cardiovascular outcomes for patients with type 2 diabetes who can't control their blood sugar with insulin therapy.

Who is the study for?
Adults aged 21-70 with Type 2 Diabetes, using insulin and certain other diabetes medications, who have a BMI of >24 to ≤40 kg/m^2. Participants should not be pregnant or breastfeeding and must use reliable contraception. They cannot have stomach disorders, severe kidney disease, recent heart issues, uncontrolled thyroid conditions, or a history of significant alcohol/substance abuse.Check my eligibility
What is being tested?
The trial is testing the Revita® System's Duodenal Mucosal Resurfacing (DMR) procedure against a sham (fake) procedure to see if it improves blood sugar control and heart health in those whose diabetes isn't well-managed by insulin alone. Participants will either receive DMR or the sham treatment and be monitored for up to 48 weeks.See study design
What are the potential side effects?
Potential side effects may include discomfort at the procedure site, digestive issues such as nausea or bloating, risks associated with sedation used during the procedure like allergic reactions or breathing difficulties, bleeding from where tissue was treated, and possible infection.

REVITALIZE 1 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a man or a woman not pregnant or breastfeeding.
Select...
I am between 21 and 70 years old.
Select...
I have type 2 diabetes, take metformin and up to 2 other diabetes medications, and need 20-60 units of insulin daily.
Select...
I am a woman who can have children, not pregnant, and agree to use two forms of birth control during the study.
Select...
I am a man or a woman not pregnant or breastfeeding.
Select...
I am between 21 and 70 years old.
Select...
I have type 2 diabetes and take 20-100 units of insulin daily, along with up to 3 other diabetes medications.

REVITALIZE 1 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Demonstrate superiority of Revita DMR to sham in improving glycemic control
Secondary outcome measures
Demonstrate superiority of Revita DMR to sham in achieving target HbA1c at 24 weeks
Demonstrate superiority of Revita DMR to sham in elimination of insulin use at 24 weeks
Demonstrate superiority of Revita DMR to sham in fasting glucose at 24 weeks
+2 more

REVITALIZE 1 Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Duodenal Mucosal Resurfacing (DMR)Active Control1 Intervention
Duodenal Mucosal Resurfacing (DMR) treatment will include hydrothermal ablation of the duodenal muscosa in an upper endoscopic procedure in patients with type 2 diabetes on insulin.
Group II: Duodenal Mucosal Resurfacing Sham (Sham)Placebo Group1 Intervention
Duodenal Mucosal Resurfacing Sham (Sham) treatment will include an upper endoscopic procedure similar to DMR treatment without hydrothermal ablation of the duodenal mucosa in patients with type 2 diabetes on insulin.

Find a Location

Who is running the clinical trial?

Fractyl Laboratories, Inc.Lead Sponsor
5 Previous Clinical Trials
249 Total Patients Enrolled
Fractyl Health, Inc.Lead Sponsor
1 Previous Clinical Trials
18 Total Patients Enrolled

Media Library

Duodenal Mucosal Resurfacing (DMR) (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT04419779 — N/A
Type 2 Diabetes Research Study Groups: Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing Sham (Sham)
Type 2 Diabetes Clinical Trial 2023: Duodenal Mucosal Resurfacing (DMR) Highlights & Side Effects. Trial Name: NCT04419779 — N/A
Duodenal Mucosal Resurfacing (DMR) (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04419779 — N/A
Type 2 Diabetes Patient Testimony for trial: Trial Name: NCT04419779 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants is this experiment accommodating?

"For this study to be successful, 560 individuals that fit the inclusion qualifications must volunteer. These volunteers can register at either Icahn School of Medicine at Mount Sinai in New york City or Mills Peninsula Health Center in San Mateo, California."

Answered by AI

Who is eligible to register for this experiment?

"The experiment is open to 560 individuals aged 21 and above, up until 70 years old. Both male and female participants must have a BMI between 24-40 kg/m2. Furthermore, they should all suffer from type 2 diabetes mellitus and be non pregnant nor lactating women."

Answered by AI

Are there multiple health care facilities conducting this clinical investigation within the city limits?

"As of now, 29 sites are offering this trial including Icahn School of Medicine at Mount Sinai in New york, Mills Peninsula Health Center in San Mateo, and University of Michigan in Ann Arbor among other locations."

Answered by AI

Are there any current enrollment opportunities for this experiment?

"Per the data on clinicaltrials.gov, this research project is still recruiting participants. It was launched March 8th 2021 and revised October 14th 2022."

Answered by AI

Does this trial extend to septuagenarian participants?

"To be eligible for this medical trial, applicants must have reached the age of majority and be under 70 years old. Patients younger than 18 are invited to participate in 193 other trials while patients over 65 can take part in 1105 studies."

Answered by AI

Who else is applying?

What state do they live in?
New Jersey
Other
California
Texas
How old are they?
65+
18 - 65
What site did they apply to?
Angel City Research , Inc.
Mayo Clinic Arizona
Baylor St. Luke's Medical Center
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
1
2
3+
0

Why did patients apply to this trial?

This one close to home. I’m trying to get my A2C down. I need something better for my diabetes.
PatientReceived no prior treatments
I am taking metformin ony and last bmi was 432. To improve the diabetes ac1 and overall health.
PatientReceived no prior treatments

How responsive is this trial?

Average response time
  • < 2 Days
Typically responds via
Email
Most responsive sites:
  1. Baylor St. Luke's Medical Center: < 48 hours
~8 spots leftby Jun 2024